For thousands of years, gold belonged to the worlds of royalty, medicine and alchemy. Today, some of the most intriguing experiments involving gold are happening somewhere very different: inside cancer research laboratories and, increasingly, carefully controlled human clinical studies.
The reason is not mystical. When gold is engineered at the nanoscale, it can interact with light, radiation and biological systems in ways that bulk gold cannot. Scientists are exploring whether those properties can help them find tumours, carry therapeutic cargo and concentrate treatment more precisely where it is needed.
That has turned an ancient metal into a remarkably modern research tool. The story is no longer purely theoretical either. Selected gold nanoparticle systems have now reached human cancer studies.
From Ancient Gold to Precision Nanomedicine
Gold nanoparticles are being investigated in cancer treatment, and selected engineered systems have reached human clinical studies, but they are not yet a routine general cancer therapy.
The strongest human evidence to date includes localized prostate-cancer studies using approximately 150 nm gold-silica nanoshells that absorb near-infrared light and convert it into heat. These trials show that a specifically designed gold nanotechnology can be used clinically under tightly controlled conditions.
That does not mean drinking colloidal gold treats cancer, and it does not mean results from one engineered nanoshell platform apply to every gold nanoparticle formulation.
What Changes When Gold Becomes Nanoscale?
Gold nanoparticles, often abbreviated AuNPs, are structures made from gold at nanometre scale. Depending on the application, researchers may engineer spheres, rods, stars, shells or other shapes and add coatings, drugs, antibodies, peptides or targeting molecules to their surfaces.
Their behaviour depends on much more than the fact that they contain gold. Important variables include:
- particle size and shape,
- surface coating and charge,
- dose and route of administration,
- how quickly the particles circulate or clear,
- whether they aggregate,
- and whether they are designed to interact with light, radiation or a therapeutic payload.
One especially important property is localized surface plasmon resonance. Certain gold nanostructures can strongly absorb or scatter selected wavelengths of light, which makes them useful in imaging and photothermal research.
The Problem Cancer Researchers Want Gold to Solve
Cancer treatment often involves a targeting problem: how can therapy affect tumour tissue while limiting damage to healthy tissue?
Gold nanoparticles offer several possible tools for that problem. They can be engineered to carry drugs, absorb light, alter local radiation effects, support imaging or combine more than one function in a single platform.
Researchers also study how nanoparticles move through tumour-associated blood vessels and tissue. The older idea that nanoparticles simply accumulate in tumours through the enhanced permeability and retention effect is now understood to be too simplistic. Tumour delivery varies greatly between cancers and patients, and biological barriers can sharply limit how much of an injected nanoparticle dose actually reaches a tumour.
A 2025 review of gold nanoparticle transport emphasized that endothelial transport, tumour structure and cellular uptake all influence whether particles reach their intended target.
Read the 2025 review of gold nanoparticle transport across tumour-associated barriers.
When Gold Nanotechnology Reached Human Cancer Trials
The most compelling part of the modern gold-and-cancer story is that some engineered gold systems have moved beyond animal experiments and into human feasibility studies.
The 2019 Pilot Study
In 2019, researchers reported a 16-patient pilot study of men with low- or intermediate-risk localized prostate cancer. Patients received an infusion of gold-silica nanoshells followed by precisely guided near-infrared laser treatment.
The nanoshells were designed to absorb the laser energy and convert it into localized heat. In that pilot, focal ablation was successfully achieved in 15 of 16 patients, and the investigators reported no serious complications or significant deterioration in the urinary and sexual-function scores they measured.
This was an important feasibility result, but the study was small and was not a randomized comparison against standard treatment.
Read the 2019 clinical pilot study on PubMed.
The 2024 Multicentre Study
A larger prospective multicentre study was published in 2024. Forty-six men were enrolled, and 44 men with 45 localized prostate lesions completed nanoparticle infusion and laser treatment.
At three months, 66% of treated patients had a negative targeted biopsy within the ablation zone. At 12 months, 73% had a negative targeted biopsy in the treated region, with systematic biopsy also performed.
Those results show that nanoparticle-directed focal photothermal ablation can produce measurable local tumour control in a selected group of patients. They do not show that gold nanoparticles are a general cure for prostate cancer or cancer more broadly.
The study was open-label and single-arm, and it tested one specific clinical system: intravenously administered AuroShell particles combined with image-guided laser activation.
Read the 2024 multicentre prostate study on PubMed.
Turning Light Into Heat: The Photothermal Idea
Photothermal therapy is one of the best-known applications of gold nanotechnology in oncology.
Certain gold nanostructures are designed to absorb near-infrared light. When exposed to the correct wavelength, they convert that energy into heat. The aim is to generate enough local temperature change to damage tumour tissue while reducing unwanted heating elsewhere.
The concept has been demonstrated extensively in laboratory and animal models. The prostate nanoshell studies are notable because they show that the principle can also be implemented in humans under image guidance.
Translation is still difficult, however. Researchers must control particle distribution, light penetration, dose, heating patterns, tumour geometry and long-term safety.
Read a 2025 review of gold nanoparticle photothermal therapy.
Could Gold Make Radiation More Precise?
Gold also attracts attention in radiation research because it has a high atomic number. When radiation interacts with gold, secondary electrons can be released, potentially increasing local energy deposition around tumour cells.
This has led to extensive work on gold nanoparticle radiosensitisation. Researchers are trying to improve tumour uptake while controlling clearance and normal-tissue exposure.
The challenge is delivery. Large particles may circulate differently from small particles, while coatings and surface chemistry can change how quickly particles are taken up by the liver, spleen, kidneys or tumour tissue.
A 2026 review describes radiosensitisation as a promising translational pathway but emphasizes that tumour-specific delivery remains a major obstacle.
Read the 2026 review of gold nanoparticle radiosensitisation.
Gold as a Microscopic Delivery Vehicle
Gold nanoparticles are also being developed as carriers. Their surfaces can be modified to hold or associate with therapeutic molecules, including conventional drugs, nucleic acids, peptides and targeting ligands.
In principle, a nanoparticle carrier could protect a payload in circulation, influence where it accumulates and release it under selected conditions. Researchers are also combining gold nanostructures with immunotherapy, photodynamic therapy and stimuli-responsive systems.
These approaches are scientifically exciting, but most remain preclinical or early translational research. A successful result in cultured cells or a mouse tumour model is not equivalent to a proven human therapy.
Imaging and Theranostics
Gold nanoparticles can also be investigated for tumour imaging because their optical and X-ray properties can be engineered for detection. Some research platforms combine diagnosis and therapy in the same particle system, an approach often called theranostics.
For example, one platform might help locate a tumour, track particle distribution and then provide a therapeutic effect through light or a carried drug.
Recent reviews continue to describe this as a major research direction, but they also emphasize that integrated nanotheranostic systems face especially difficult manufacturing and regulatory challenges because every added function increases complexity.
Read a 2026 review of gold nanoparticle cancer theranostics.
Why Promising Animal Results Often Fail to Become Treatments
The gap between a compelling laboratory study and an approved cancer treatment is enormous.
A 2026 review of oncology nanotheranostics described several recurring barriers:
- inconsistent tumour delivery,
- batch-to-batch manufacturing variability,
- difficulty scaling complex particles under Good Manufacturing Practice conditions,
- protein-corona formation and immune interactions,
- long-term biodistribution and safety questions,
- limited ability of some animal models to predict human behaviour,
- and complex regulatory pathways for combination products.
These are not minor details. They are among the main reasons relatively few experimental nanoparticle systems become routine oncology tools.
Safety Depends on the Exact Nanoparticle
It is misleading to describe gold nanoparticles as simply “safe” or “toxic” as a single category. Their biological behaviour changes with particle design.
Important variables include size, shape, surface coating, charge, dose, route of administration, circulation time and the organs in which the particles accumulate.
A review of more than 20 human clinical studies involving gold nanoparticle systems found no major safety signal across the limited trials reviewed, but the authors stressed that total participant numbers remained small and that larger, blinded, multicentre studies were needed.
Engineered Cancer Nanoparticles Are Not the Same as Consumer Colloidal Gold
The gold systems used in oncology research are usually highly engineered. Researchers control dimensions, coatings, surface chemistry, sterility, dose, route of administration and often an external activation method such as laser light or radiation.
A consumer colloidal-gold liquid is a different product category. Even if both contain nanoscale or finely dispersed gold, that shared ingredient does not make them biologically or clinically interchangeable.
The prostate nanoshell trials therefore do not show that drinking colloidal gold treats cancer. They show that one purpose-built gold nanotechnology can be used as part of a controlled image-guided cancer procedure.
For a broader explanation of this distinction, see What Is Colloidal Gold? and the Gold Nanoparticles Research Library.
How Strong Is the Evidence?
| Research area | Current evidence | What can responsibly be said |
|---|---|---|
| Prostate nanoshell photothermal therapy | Human pilot and multicentre single-arm feasibility studies. | A specific gold-silica nanoshell system has shown clinical feasibility and local tumour-ablation activity in selected patients. |
| Photothermal therapy more broadly | Extensive preclinical work, with limited human translation. | Mechanistically strong and clinically plausible, but not a routine general cancer treatment. |
| Radiosensitisation | Large preclinical literature, active translational research. | Gold can enhance local radiation effects under experimental conditions, but delivery remains a major challenge. |
| Drug and gene delivery | Predominantly laboratory and animal research with selected translational programmes. | Gold can serve as a configurable carrier platform, but most systems are not clinically established. |
| Consumer colloidal gold | No established clinical evidence for treating cancer. | Results from engineered oncology nanomaterials should not be transferred to an oral consumer product. |
Where the Gold and Cancer Story Stands Today
Gold nanotechnology has moved further in oncology than many people realise. It is no longer accurate to describe every gold-and-cancer idea as purely theoretical, because engineered gold nanoshells have already been tested in human prostate-cancer studies.
At the same time, it would be equally inaccurate to say that gold nanoparticles are already revolutionising cancer care across the board.
The most defensible conclusion is more interesting: gold is a highly adaptable nanomaterial that has demonstrated real clinical feasibility in selected systems, while most of its proposed oncology applications remain experimental.
The next advances will depend not only on whether gold can affect tumour tissue, but on whether scientists can manufacture reproducible particles, deliver enough of them to the right place, demonstrate long-term safety and prove meaningful benefit in well-controlled human trials.
Frequently Asked Questions
Are gold nanoparticles already used to treat cancer?
Specific engineered gold nanoparticle systems have reached human clinical studies, including gold-silica nanoshell photothermal ablation in localized prostate cancer. Gold nanoparticle therapy is not yet a routine general treatment for cancer.
What did the prostate cancer gold nanoshell studies find?
A 2019 pilot treated 16 patients and reported successful focal ablation in 15. A larger multicentre study later treated 44 men, with 73% showing no cancer in the treated target on biopsy at 12 months. Both studies were non-randomized feasibility studies of a specific nanoshell-and-laser system.
How do gold nanoparticles kill cancer cells in photothermal therapy?
Selected gold nanostructures absorb near-infrared light and convert it into heat. When enough heat is generated locally, tumour tissue can be damaged or ablated.
Can gold nanoparticles make radiotherapy stronger?
Laboratory research shows that gold can increase local radiation energy deposition and may act as a radiosensitiser. Clinical translation depends on achieving reliable tumour uptake while limiting exposure elsewhere.
Is colloidal gold the same as the gold used in cancer nanomedicine?
No. Clinical and experimental oncology platforms use purpose-built nanoparticles with defined sizes, coatings, doses and delivery methods. Those results cannot be assumed to apply to a consumer colloidal-gold liquid.
Can someone use colloidal gold instead of cancer treatment?
No. There is no established clinical evidence that consumer colloidal gold treats cancer, and it should not replace oncology care recommended by a qualified medical team.
Key References
- Rastinehad AR, et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proc Natl Acad Sci U S A. 2019. PubMed PMID 31451630.
- Canfield SE, et al. A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation. J Urol. 2024. PubMed PMID 39226591.
- Clinical translation of gold nanoparticles. 2022. PubMed PMID 36045273.
- Applications and safety of gold nanoparticles as therapeutic devices in clinical trials. 2023. PubMed PMID 37842655.
- Gold nanoparticle transport across tumour-associated biological barriers: in vitro models, imaging, and quantification. 2025. PubMed PMID 41358374.
- Tumor radiosensitization with gold nanoparticles: evolving strategies to improve tumoral gold uptake and catalyze future clinical translation. 2026. PubMed PMID 41743230.
- Application Advances of Gold Nanoparticles in Cancer Theranostics. 2026. PubMed PMID 42074099.
- Navigating the translational Valley of death in oncology nanotheranostics. 2026. PubMed PMID 42473742.
